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Although significant efforts have been made to
understand the mechanisms of caspase activation
during apoptosis, many questions remain regarding
how and when executioner caspases get activated.
We describe the design and synthesis of an activity-
based probe that labels caspase-3/-6/-7, allowing
direct monitoring of all executioner caspases simul-
taneously. This probe has enhanced in vivo proper-
ties and reduced cross-reactivity compared to our
previously reported probe, AB50. Using this probe,
we find that caspase-6 undergoes a conformational
change and can bind substrates even in the absence
of cleavage of the proenzyme. We also demonstrate
that caspase-6 activation does not require active
caspase-3/-7, suggesting that it may autoactivate
or be cleaved by other proteases. Together, our
results suggest that caspase-6 activation proceeds
through a unique mechanism that may be important
for its diverse biological functions.
INTRODUCTION
The caspases are cysteine proteases that play key roles in medi-
ating apoptosis, a highly regulated form of cell death critical
for normal development, tissue homeostasis, and removal of
damaged cells. Recently, our group developed fluorescent
activity-based probes that can be used to detect caspase
activation upon induction of apoptosis both in vitro and in vivo
(Edgington et al., 2009). Because these probes form a stable,
covalent bond with the active-site cysteine, they can be used
to monitor caspase activity using a wide variety of detection
strategies, including fluorescent SDS-PAGE, flow cytometry,
microscopy, and optical imaging of tissues and whole organ-
isms. Although our initial peptide acyloxymethyl ketone
(AOMK) probe, AB50, is a valuable reagent for the study of
caspase activation, it suffers from cross-reactivity with the lyso-
somal cysteine protease legumain and also predominantly labels
the executioner caspase-3 and -7 (Edgington et al., 2009).340 Chemistry & Biology 19, 340–352, March 23, 2012 ª2012 ElsevieTherefore, probes with greater selectivity over nonapoptotic
proteases and overall broader reactivity within the caspase
family would be useful for monitoring multiple caspase activation
pathways under different death stimuli.
Caspase-6, like caspase-3 and -7, is dimeric in solution, and
cleavage of the prodomain and intersubunit linker produces
the mature enzyme complex composed of a heterotetramer of
two large and two small subunits. Caspase-6 has recently
been reported to self-activate, at least in vitro (Klaiman et al.,
2009;Wang et al., 2010). The roles andmechanism of caspase-6
activation during apoptosis are not well understood and vary
depending on the system being analyzed. Caspase-6 activation
has been postulated to both precede (Allsopp et al., 2000) and
depend on (Inoue et al., 2009; Slee et al., 1999, 2001) caspase-3
activity. It can also become activated in the absence of
caspase-3 (Inoue et al., 2009). In primary neurons, caspase-6
has also been reported to act downstream of caspase-1 (Guo
et al., 2006). Additionally, once activated by the intrinsic
pathway, caspase-6 can cleave the initiator caspase-8 in the
cytosol (Cowling and Downward, 2002). Unlike the other execu-
tioner caspases, caspase-6 cleaves nuclear lamin A/C during
programmed cell death, which promotes chromatin condensa-
tion and the formation of apoptotic bodies (Rao et al., 1996;
Ruchaud et al., 2002; Takahashi et al., 1996).
In addition to its roles in apoptosis, caspase-6 is also
proposed to be involved in several neurodegenerative disorders.
In mouse models of Huntington disease (HD), resistance to
cleavage of the huntingtin protein at a caspase-6 site is sufficient
to protect mice from neurological and behavioral abnormalities
associated with pathogenesis as well as NMDA receptor-
mediated excitotoxicity, suggesting key roles for caspase-6 in
the development of HD (Graham et al., 2006, 2010; Pouladi
et al., 2009). In Alzheimer’s disease, caspase-6 has been shown
to be active in the early stages of cognitive impairment and
mediates cleavage of tau, amyloid-b peptide, and other
cytoskeletal components leading to plaque formation and neuro-
fibrillary tangles associated with disease progression (Guo et al.,
2004; Klaiman et al., 2008). In direct contrast, cleavage of DJ-1
by caspase-6 plays a protective role, and mutations of the
caspase-6 cleavage site on DJ-1 are associated with pathogen-
esis of Parkinson’s disease (Giaime et al., 2010).
Because of this diversity of biological roles for caspase-6,
improved tools to study this protease could lead to a greaterr Ltd All rights reserved
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and during disease progression. Here we describe the synthesis
and testing of a fluorescent activity-based probe designed to
target caspase-6. The optimal probe that we identified, LE22,
efficiently labels caspase-6 but retains activity toward caspase-3
and -7. Therefore, it can be used to monitor the activity of all
three executioner caspases simultaneously. In addition, LE22
shows enhanced labeling of caspases in vivo as well as overall
reduced cross-reactivity toward the off-target protease legu-
main compared to our previous-generation probe, AB50 (Edg-
ington et al., 2009). Using this probe, we show that caspase-6
is activated through multiple partially cleaved complexes that
productively bind the probe and are in a complex with mature
forms of caspase-6. Furthermore, we show that caspase-6 can
be activated in the absence of active caspase-3 and -7. These
results suggest a unique activation mechanism for caspase-6
compared to the other executioner caspases that may be rele-
vant to its multiple diverse roles in cell biology.
RESULTS AND DISCUSSION
Development of Activity-Based Probes for Caspase-6
In order to develop a probe to monitor caspase-6 activity, we
used AB50 (Edgington et al., 2009) as a starting scaffold and
changed the peptide specificity region based on reported
caspase-6 substrate preferences (Figure 1A; see Figure S1 avail-
able online). We chose the sequence Val-Glu-Ile-Asp (VEID)
because it is the sequence recognized by caspase-6 on lamin
A/C, a substrate that is not effectively processed by the other
executioner caspases (Rao et al., 1996). Furthermore, many
commercially available substrates and inhibitors for caspase-6
also make use of this sequence. We also designed a probe
containing the sequence Ile-Val-Leu-Asp (IVLD) corresponding
to the site on the huntingtin protein that has been shown to
be cleaved by caspase-6 to generate neurotoxic fragments
(Graham et al., 2010). Finally, we used the optimal substrate
sequence for caspase-6, Val-Glu-His-Asp (VEHD), reported
from fluorogenic substrate screening assays (Thornberry et al.,
1997). We also screened purified, recombinant caspase-6
against our previously reported positional scanning library of
AOMK inhibitors (Berger et al., 2006). This screen indicated
that caspase-6 strongly prefers threonine at both P2 and P4
positions, whereas caspase-3 does not (Figure S2). Therefore,
we also synthesized a probe containing the sequence Thr-Glu-
Thr-Asp (TETD). All of the probes were readily synthesized in
Cy5-labeled form using a combination of solid-phase and
solution-phase synthesis (Scheme S1).
To test these probes for caspase-6 labeling, we used an
in vitro model of apoptosis in which human COLO205 colorectal
cancer cells were stimulated with a death receptor 5 agonist
antibody (anti-DR5) to induce the extrinsic cell death pathway.
Labeling of intact cells with each of the probes showed similar
patterns; however, the probe based on the lamin cleavage
sequence, LE22, was by far the most potent (Figure S1C). We
next compared the labeling of LE22 to our previously reported
probe, AB50 (Figure 1B). Most strikingly, we found that LE22
was more effective at labeling caspases than AB50. This may
be due to a combination of increased cell permeability of
the probe as well as increased potency for the executionerChemistry & Biology 19, 3caspases. Although the labeling profile of LE22 was similar to
AB50, it clearly labeled an 18 kDa protein and several higher-
molecular-weight proteins between 30 and 36 kDa that were
not labeled by AB50 (Figure 1B). Because LE22 was designed
to target caspase-6, we hypothesized that these additional
labeled proteinsmay bemultiple forms of caspase-6. As an initial
test of this hypothesis, we pretreated cells with the AOMK inhib-
itor AB13 (Berger et al., 2006) that we previously showed to be
selective for mature forms of caspase-3 and -7 prior to labeling
with LE22 (Figure 1B). Interestingly, inhibitor pretreatment
completely blocked labeling of all of the AB50-labeled proteins
but had no effect on the labeling of the LE22-specific 18 kDa
and 30–36 kDa species.
To confirm the identity of the labeled caspases, we performed
immunoprecipitation studies using antibodies raised against the
cleaved forms of caspase-3, -6, and -7 (Figure 1C). As expected,
we were able to precipitate cleaved forms of caspase-3 and -7
in cells labeled with AB50 or LE22. The caspase-6 antibody
immunoprecipitated both the 18 kDa protein as well as the
higher-molecular-weight (30–36 kDa) proteins that were only
found in the LE22-labeled cells. These data suggest that LE22
is an overall more potent and sensitive probe than AB50 that
labels caspase-3 and -6, and to a lesser extent caspase-7.
Cross-Reactivity of Caspase Probes
In our previous studies, we found that the lysosomal cysteine
protease legumain is the major off target of the AB50 probe
(Edgington et al., 2009). The active site of this enzyme has
a similar overall fold to the caspases but is thought to predomi-
nantly cleave protein substrates after asparagine residues
(Abe et al., 1993). However, legumain is also able to bind aspartic
acid-containing probes at the reduced pH of the lysosome (Kato
et al., 2005; Sexton et al., 2007). To monitor selectivity, we used
both AB50 and LE22 to label RAW cells, an immortalized mouse
macrophage line that expresses high levels of active legumain
and cathepsins (Figure 2A). As reported previously, we observed
significant labeling of legumain by AB50. LE22, on the other
hand, showed no labeling of legumain, even when used at high
concentrations, indicating a markedly reduced cross-reactivity
for this probe.
We also evaluated the specificity of both probes in vivo by
treating wild-type mice and analyzing kidney and liver extracts
by fluorescence imaging and SDS-PAGE (Figure 2B). As a result
of the high levels of expression of legumain in these organs, LE22
exhibits some cross-reactivity toward this protease; however,
the cross-reactivity was considerably less than AB50, consistent
with the selectivity patterns observed for these probes in RAW
cells (Figure 2B).
Application of LE22 to In Vivo Models of Apoptosis
We next determined whether the increased potency of LE22
toward caspase-3, -6, and -7 relative to AB50was also observed
in in vivo models of cell death. We initially tested both probes in
a mouse model in which dexamethasone (dex) was used to
induce apoptosis in CD4+/CD8+ thymocytes (Figure 3A). For
both probes, we observed a dex-dependent increase in both
thymus fluorescence and caspase labeling as assessed by
SDS-PAGE (Figure 3A). The dex-induced caspase labeling could
also be blocked by pretreating mice with the broad-spectrum40–352, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 341
Figure 1. Direct Comparison of LE22 and AB50 Labeling in Intact Apoptotic Cells
(A) Structures of the previous-generation caspase probe, AB50, and the optimal probe from the series, LE22.
(B) Fluorescent SDS-PAGE comparing LE22 and AB50 labeling of apoptotic human colorectal cancer COLO205 cells. Cells were induced to undergo apoptosis
using anti-DR5, and intact cells were labeled with each probe at the indicated concentrations. Where indicated, the caspase-3 and -7 specific inhibitor AB13 was
added prior to labeling with the probes. Total protein lysates were analyzed by SDS-PAGE followed by scanning for Cy5 fluorescence using a flatbed laser
scanner. An autofluorescent protein is indicated with a #. Arrows highlight caspase-6 species that are labeled by LE22 but not by AB50. The bottom panel shows
enhanced contrast of the boxed region for easier viewing of the high-molecular-weight bands.
(C) Immunoprecipitations using the indicated cleaved caspase antibodies to confirm the identity of labeled proteins in the 5 mM samples in (B). Faint bands in the
pull-downs that are difficult to see are noted with an asterisk, and the bottom panel shows enhanced contrast for easier viewing.
See also Figures S1 and S2.
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Figure 2. Cross-Reactivity of Probes toward Other Cysteine Proteases
(A) Fluorescence SDS-PAGE showing labeling in RAW cells. Intact RAW cell mouse macrophages were labeled with the indicated concentrations of LE22 or
AB50. Total protein lysates were harvested and resolved by SDS-PAGE followed by scanning on a flatbed laser scanner for Cy5 fluorescence. An autofluorescent
background protein in the no-probe control tumors is marked by a #.
(B) Images of kidney and liver fluorescence after probe injection and corresponding SDS-PAGE analysis. LE22 or AB50was injected by tail vein into normal BALB/
cmice. Kidney and liver were harvested after 4 hr of circulation, and probe fluorescence in the tissues was imaged using a CCD camera. Note differences in scale.
Tissues were then homogenized and analyzed by SDS-PAGE followed by fluorescence scanning. Labeled proteases are indicated, and an autofluorescent
background protein in the no-probe control tumors is marked by a #.
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firmed that AB50 labeled caspase-3 and a small amount of
caspase-6, whereas LE22 labeled caspase-3 and -6 to a similar
extent (Figure 3B). Caspase-7 activity was detected by both
probes, but to a greater extent by AB50. In addition, in agree-
ment with our results in the mouse RAW cells and normal
mice, we only observed legumain labeling by AB50 and not
by LE22.
We also used LE22 and AB50 to label caspases in tumors
induced to undergo apoptosis by chemotherapy. In this model,
human COLO205 colorectal tumor cells were xenografted onto
the backs of nude mice and later induced to undergo apoptosis
by treatment with the anti-DR5 antibody. Whereas both probes
showed an anti-DR5-dependent increase in fluorescence within
the tumor, LE22-treated tumors were brighter and showed better
contrast over nontreated controls (Figure 4A). After noninvasive
imaging, we removed tumors and performed ex vivo imaging
followed by SDS-PAGE analysis of tumor lysates (Figure 4B).
Again we found that fluorescence increased in response to
anti-DR5 antibody treatment, and signals from LE22-treated
tumors were overall much brighter than those from AB50-treated
tumors. Biochemical analysis of the tumor tissues verified that
fluorescence intensity correlated with levels of caspase labeling.
Again, LE22 showed stronger labeling of caspases than AB50,
and also labeled less legumain.
We also wanted to determine whether LE22 could be used
ex vivo to monitor caspase-6 activation and maturation. We
therefore labeled extracts from anti-DR5-treated tumors with
AB50 and LE22 and analyzed the labeling by SDS-PAGE. As
we observed in intact COLO205 cells in vitro, there is a clear
increase in labeling intensity of caspases for LE22 compared
to AB50 (Figure 4C). We also used the caspase-3 and -7 specific
inhibitor AB13 to block the activity of these two proteases. This
treatment demonstrated that AB13 blocked labeling of all butChemistry & Biology 19, 3three species by LE22 and completely blocked labeling of all
species by AB50. Immunoprecipitation using caspase-3, -6,
and -7 specific antibodies confirmed that the remaining proteins
labeled by LE22 were in fact various forms of caspase-6
(Figure 4D). Overall, the labeling patterns were strikingly similar
to what we observed in vivo, except that one of the
procaspase-6 forms was obscured by legumain in the in vivo
samples (legumain was not observed in lysates because labeling
was carried out at neutral pH).
Monitoring Caspase-6 Activation with LE22
To determine whether differences in the sensitivity of AB50
and LE22 were due to permeability or uptake of the probes,
we examined probe labeling in apoptotic lysates. As before,
COLO205 cells were treated with anti-DR5 for 4 hr, followed by
hypotonic lysis and subsequent probe labeling for 30 min (Fig-
ure 5A). Overall, we observed approximately 10-fold enhanced
potency of LE22 compared to AB50. Interestingly, unlike in intact
cells (Figure 1B), AB50 was able to label the mature form of
caspase-6 in lysates. This result suggests that part of the reason
for the lack of labeling of caspase-6 by AB50 may be due to
reduced access of the probe to the intracellular caspase-6
pool. Cleaved caspase-6 has been shown to accumulate in the
nucleus of COS cells upon staurosporine treatment (Warby
et al., 2008), suggesting that AB50 could have reduced nuclear
access.
In lysates, we saw more pronounced labeling of the larger
forms of caspase-6, which were appropriately sized to be pro-
forms that had not been cleaved between the large and small
subunits (Figure 5B). We were initially surprised to see labeling
of these forms, as activation of caspase-6 is thought to depend
on removal of the prodomain and cleavage of the intersubunit
linker. We also did not expect these forms to immunoprecipitate
with an antibody that recognizes cleaved forms of caspase-640–352, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 343
Figure 3. Comparison of LE22 and AB50 in Dexamethasone-Induced Thymocyte Apoptosis
(A) Fluorescent images of apoptotic and control thymi and corresponding SDS-PAGE analysis. BALB/c mice were injected with dexamethasone or vehicle for
12 hr followed by injection of either LE22 or AB50 by tail vein. A subset of the dex-treated mice was pretreated with a caspase inhibitor, AB46, prior to probe
injection. After 4 hr, thymi were harvested and imaged ex vivo for probe accumulation. Thymus proteins were then resolved by SDS-PAGE and scanned for Cy5
fluorescence using a flatbed scanner. An autofluorescent background protein in the no-probe (NP) control tumors is marked by a #.
(B) Immunoprecipitations of samples shown in (A). The first sample in each dex-treated lane for LE22 and AB50 was immunoprecipitated with the indicated
antibody and analyzed by SDS-PAGE.
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terminus of the large subunit of caspase-6, and therefore should
not detect full-length forms. The most plausible explanation for
our results was that we were precipitating caspase-6 dimers
in which a labeled, full-length uncleaved monomer was in
a complex with a cleaved monomer. This half-cleaved complex
would be similar to what has previously been reported for
caspase-7 (Berger et al., 2006; Denault et al., 2006).
To test this hypothesis, we performed immunoprecipitation
using probe-labeled apoptotic lysates that were denatured by
boiling in SDS sample buffer using an antibody that recognizes
only cleaved caspase-6 (Figure 5D). Under denaturing condi-
tions, the cleaved caspase-6 antibody precipitated negligible
amounts of the full-length forms, suggesting that proforms of
caspase-6 can be labeled by active-site probes and that at least344 Chemistry & Biology 19, 340–352, March 23, 2012 ª2012 Elseviesome fraction of these proforms can be isolated in complex with
cleaved forms of caspase-6. To further confirm that the single-
chain (uncleaved) forms of caspase-6 possess catalytic activity,
we pretreated lysates with two different inhibitors, AB46 and
LE33, a version of LE22 in which the Cy5 tag was replaced
with biotin (Figure 5E). These results confirmed that active-site-
directed inhibitors could block the labeling of the higher-
molecular-weight proforms of caspase-6 by LE22. AB13, the
caspase-3/-7 selective inhibitor, however, was unable to block
labeling of those same proforms.
A Conformational Change Is Permissive for Activation
in the Absence of Cleavage
To gainmore insight into the activationmechanismof caspase-6,
we generated several cleavage-site mutants in which ther Ltd All rights reserved
Figure 4. Comparison of LE22 and AB50 in COLO205 Tumors Treated with Anti-DR5 Antibody
(A) Noninvasive imaging of apoptosis in tumor-bearing mice. Nude mice bearing COLO205 tumors were treated with anti-DR5 antibody or vehicle for 12 hr
followed by intravenous injection of either LE22 or AB50. After 1 hr of circulation, live mice were imaged using an IVIS 100. Red arrows indicate the location of the
tumors.
(B) Ex vivo imaging of tumors shown in (A) and corresponding biochemical analysis. Tumors were imaged ex vivo using epifluorescence on an FMT machine and
then homogenized. Total protein lysates were analyzed by SDS-PAGE and scanned for Cy5 fluorescence. An autofluorescent background protein in the no-probe
control tumors is marked by a #.
(C) Fluorescent SDS-PAGE analysis of tumors labeled ex vivo. Apoptosis was induced in a COLO205 tumor as in (A); however, the tumor was removed prior to
probe administration, and tumor lysates were labeled with LE22 or AB50 at the indicated concentrations. Where noted, the AB13 inhibitor was added to block
caspase-3 and -7 labeling. Vehicle-treated control tumors were also included in the analysis.
(D) Immunoprecipitations of tumor lysates labeled with 1 mM LE22 with the indicated antibodies to confirm the identity of labeled caspases. Weak bands in the
immunoprecipitations are indicated by an asterisk.
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Figure 5. Direct Comparison of LE22 and AB50 Labeling in Apoptotic Lysates
(A) Fluorescent SDS-PAGE of labeled COLO205 lysates. Apoptosis was induced in COLO205 cells with an anti-DR5 antibody and cells were harvested. Lysates
were then labeled with LE22 or AB50 at the indicated concentrations. AB13 was added to samples as indicated to selectively block caspase-3 and -7 labeling.
Protein was resolved by SDS-PAGE and scanned for Cy5 fluorescence.
(B) Schematic of the proposed forms of caspase-6 based on known cleavage sites. From left to right, prodomain, large subunit (p18), intersubunit linker, and small
subunit (p11). The active site cysteine (the site at which the probe binds) is depicted by a star. Predicted sizes are listed at the left.
(C) Immunoprecipitations of lysates labeled with 1 mM LE22. Five times as much protein was used as in (A) to ensure adequate pull-down of less abundantly
labeled proteins. Faintly labeled species that are difficult to see in the pull-downs are marked by an asterisk. Ctrl indicates an immunoprecipitation that was
performed in the absence of antibody to account for nonspecific sticking of proteins to the protein A/G beads.
(D) Immunoprecipitations of LE22-labeled lysates with antibodies for the cleaved and full-length caspase-6 species in their native, folded state (left lanes) or
denatured by boiling in SDS sample buffer (right lanes).
(E) Full-length capase-6 labeling by LE22 in intact apoptotic cells was blocked by pretreatment with AB46 and biotinylated LE22 (LE33), but not by pretreatment
with AB13. An autofluorescent band is denoted with a #.
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the linker region were converted to alanine (A) (Figure S3).
Compared to wild-type, the reduction in activity of the D23A or346 Chemistry & Biology 19, 340–352, March 23, 2012 ª2012 ElsevieD179A single mutants was minimal, and even the D23A/D179A
double mutant showed only a 2-fold decrease in Kcat/KM
(Table S1). The most dramatic reduction in activity, however,r Ltd All rights reserved
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D179A mutations further reduced the activity of D193A. This
confirms the earlier finding that caspase-6 can autoprocess at
D193, whereas D179 requires an additional enzyme for cleavage
(Wang et al., 2010). Cleaving the D193A mutants with 1%
caspase-3 overnight increased the activity by about 40-fold.
However, activity failed to reach levels expected for fully pro-
cessed caspase-6, indicating that processing of the linker at
D193 is absolutely essential to generate a fully active caspase-6
species. Interestingly, the amount of active enzyme in the
preparations of noncleaved caspase-6 as determined by titration
with Z-VAD-FMK was only about 10%–15% of what was ex-
pected based on absorption at 280 nm, whereas incubation
with caspase-3 overnight led to activation of 100% of the
caspase-6 species in the preparations (not shown). Thus, in the
total pool of noncleaved caspase-6, only a fraction has activity,
whereas the entire pool has the capacity to generate activity.
Because the noncleavable caspase-6 mutants retained
activity, albeit very little, we decided to utilize LE22 to visualize
the active species of recombinant caspase-6 (Figure 6A). The
full-length caspase-6 species containing D193A readily bound
the probe (lanes 5, 7, and 8), albeit to a lesser degree than those
species processed at D193 (lanes 1, 3, 4, and 6). Addition of 1%
active caspase-3 to the D193A or D23A/D193Amutants dramat-
ically increased probe labeling (lanes 9 and 10). The active-site
mutants of both caspase-6 and caspase-3 (lanes 2 and 12,
respectively) were not labeled by the probe at all, indicating
that probe binding is specific and depends on activity. In addi-
tion, several higher-molecular-weight species were also labeled
by the probe. These are not likely to be contaminants carried
over from Escherichia coli, because they are not detected in
the Cys mutant species and could represent aggregates of
active caspase-6.
Executioner caspases have been suggested to fluctuate
between an ‘‘active’’ and an ‘‘inactive’’ conformation, with pro-
cessing of the intersubunit linker stabilizing the active conforma-
tion (Fuentes-Prior and Salvesen, 2004; Gray et al., 2010). In
theory, an inhibitor or active-site probe such as LE22 could stabi-
lize this active conformation. If this were the case, we would
expect to see a steady increase in labeling over time when the
uncleavable caspase-6 is labeled with the probe. However, we
found that although the uncleaved species labels more slowly
than the wild-type (as expected from its decreased kcat),
maximum labeling of all species was achieved after 90 min of
incubation with an excess of probe (Figure S4A). This labeling
was significantly lower (7-fold) than the maximum labeling of
WT caspase-6, even though equal amounts of total protein
were used in the experiment (Figure S4B). This suggests that
only a fraction of the uncleaved caspase-6 species is in an active
conformation and, although this fraction labels more slowly than
processed caspase-6, it does not increase over time.
The executioner caspase-3 and -7 have been described to
form obligate dimers (Boatright et al., 2003), and dimerization
is an absolute requirement for caspase activation. We wondered
whether the uncleavable caspase-6 mutants were primarily ex-
pressed as inactive monomers, whereas only the fraction that
was labeled by LE22 formed active dimers. To investigate this
hypothesis, we analyzed all caspase-6 species on a native
pore limit gel after labeling with LE22 (Figure 6B). On suchChemistry & Biology 19, 3a gel, a native protein sample is resolved on a 4%–20% poly-
acrylamide gradient. Migration of a protein or protein complex
is limited by the pore size of the polyacrylamide, and thus
a protein complex will reach equilibrium higher up in the gel
(at a larger pore size) than the individual proteins would (Barrett
et al., 1979; Boatright et al., 2003). To our surprise, the inactive,
unlabeled species ran higher in the gel than the labeled species,
which ran at approximately the same molecular weight as the
caspase-3 dimer irrespective of linker or prodomain processing.
Probe-labeled species resolved lower on the gel, suggesting
that either native caspase-6 forms a higher oligomer or that inac-
tive, single-chain caspase-6 is partially unfolded and therefore
migrates more slowly through the gel. In support of the latter
hypothesis, the crystal structure of ligand-free caspase-6
reveals a misalignment of active-site residues, which is not
observed for caspase-3 or -7 (Baumgartner et al., 2009). When
we compared the different species of single-chain caspase-6
with WT on native gel either with or without LE22 labeling, we
observed a significant shift upon probe binding (Figure S4D),
suggesting that caspase-6 folds around its ligand, as has been
suggested (Vaidya et al., 2011).
To study the behavior of natural (endogenous) caspase-6
upon activation, we activated caspase-9 in cytosolic extracts
from HEK293T cells by adding cytochrome c and dATP, a
commonly used model for caspase activation (Figures 6C
and 6D) (Stennicke et al., 1999). As indicated by probe labeling,
both caspase-3 and -6 are activated within 30 min and are fully
processed within 60 min. At 30 min, a partially processed
species of caspase-3 can also be observed that has activity,
as indicated by probe binding, and is detected by the active
caspase-3 antibody. We then probed the blots successively
with antibodies against full-length and cleaved caspase-3
and -6 to distinguish between specific and nonspecific antibody
recognition. Although both caspase-6 and -3 are cleaved during
activation, only caspase-6 undergoes a dramatic change in
conformation as observed on the native gel (lower panels).
Caspase-3 migrates at the same MW, whether or not it is
cleaved/active, whereas active caspase-6 shifts to a lower MW
relative to inactive caspase-6 upon activation. Furthermore,
labeling of uncleaved caspase-6 can also be observed, both
on the denatured and the native gel.
Altogether, our data suggest that a conformational change is
permissive for initial caspase-6 activation, whereas cleavage,
in particular autoprocessing of D193, further enhances activity
and stabilizes the active conformation.
Kinetic Studies of Caspase Activation Using Activity-
Based Probes
We next used LE22 to examine the dynamics of executioner
caspase activation in intact cells after induction of a death stim-
ulus. For these studies, we treated COLO205 cells with anti-DR5
antibody over an 8 hr time period and labeled with LE22 or AB50
in the final 30 min of the experiment (Figure 7A). We found that
the p19 form of caspase-3 is active at early time points and
matures over time, leading to increased activity of the p17
form. Interestingly, caspase-6 activates more slowly than
caspase-3, and shows the most activity at late time points. In
intact cells, the proforms of caspase-6 gradually show increased
activity over time. In parallel, we also conducted a similar time40–352, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 347
Figure 6. Caspase-6 Undergoes a Conformational Change upon Activation
(A and B) Recombinant caspase-6 as well as wild-type and the active-site mutant (C/A) of caspase-3 were incubated with an excess of LE22 (4 mM) for 3 hr and
analyzed by SDS-PAGE (A) or on pore limit native PAGE (B). D193Amutants of caspase-3 were cleaved with 1% caspase-3 overnight where indicated (+C3). The
gel was first scanned on a fluorescent scanner to detect the probe signal and then stained with Coomassie and rescanned to detect total protein. The two figures
were then overlaid to visualize the species of caspase-6 that were active (i.e., bound the probe; red) relative to species that were not catalytically active (i.e., only
stained blue; blue).
(C and D) Hypotonic lysates from 293T cells were activated by the addition of cytochrome c and dATP. Samples were taken before, after 30 min, and after 60 min
of cytochrome c addition, labeled with LE22 for 30 min at 37C, and analyzed by western blot after separating the proteins either by SDS-PAGE (upper panels) or
by pore limit native PAGE (lower panels). Blots were probed for total and active caspase-3 (C) or caspase-6 (D). The signal obtained for the caspase blots is
displayed in green, and the signal from LE22 is in red. Full-length and cleaved caspase species are indicated by arrows. Notice that on the pore limit gel, full-length
and cleaved caspase-3 run at the same molecular weight.
See also Figures S3 and S4 and Table S1.
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Figure 7. Monitoring Maturation of Execu-
tioner Caspases during Apoptosis
(A) COLO205 cells were stimulated with anti-DR5
to initiate apoptosis for the indicated period of
time. During the last 30 min of treatment, intact
cells were labeled with 1 mM LE22 or AB50. Cells
were then lysed and subjected to SDS-PAGE
analysis. The bottom panel shows enhanced
contrast of the boxed region for easier viewing of
the high-molecular-weight proteins.
(B) Cells were treated in parallel to those in (A);
however, labeling with 1 mM LE22 was performed
postlysis. In the right panel, 10 mM AB13 was
added prior to LE22 to allow for specific labeling of
caspase-6.
(C) Cells were treated as above, except AB13 was
added at the time of anti-DR5 stimulation to block
caspase-3/-7 activity throughout the course of the
experiment. The bottom panel shows enhanced
contrast of the boxed region for easier viewing of
the high-molecular-weight bands.
See also Figure S5.
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ure 7B). In these samples, we observed a sharp increase in
activity of the proforms of caspase-6 immediately upon anti-
DR5 stimulation. This activity remained relatively constant over
time (Figure 7B). To obtain a clearer picture of caspase-6 activity,
we also used AB13 to block labeling of caspase-3 and -7 in the
lysates before labeling with LE22 (Figure 7B). Using this method,
wewere able to clearly identify all of the sixmajor predicted forms
of caspase-6 (see Figure 5B). Additionally, we performed analo-
gousstudies in Jurkat cells usinga variety of intrinsic andextrinsic
death stimuli and observed similar trends in caspase-6 activation
(Figure S5). The kinetics of activation were slower with anti-DR5,
anti-Fas, or staurosporine thanwith etoposide.However, the pro-
forms of caspase-6 increase in activity under all stimuli.
Finally, we performed a kinetic study in which AB13 was
added at the time of anti-DR5 treatment to block caspase-3/-7
activity throughout the experiment (Figure 7C). If these execu-Chemistry & Biology 19, 340–352, March 23, 2012tioner caspases were essential for cas-
pase-6 activation in this model, we would
expect to see dramatic changes in the
kinetics of its maturation. However, the
caspase-6 labeling pattern remained
relatively unchanged. Whereas autopro-
cessing occurs at D193, full maturation
to the p18 form of caspase-6 would not
be expected to occur without cleavage
at D179. This suggests either that cas-
pase-6 is capable of autoactivation or
that other caspases are able to cleave
at D179.
DISCUSSION
The process of activating apoptosis is
complex and involves multiple caspase
proteases. Although a great deal is known
about the multiple steps in the signalingcascade, still relatively little is known about the details of how
and when specific caspases are activated. In particular, the
executioner caspase-6 has been proposed to play roles in clas-
sical death signaling, but it also may play important functions in
regulation of protein turnover and neuronal function. In addition,
it is not clear how and when this protease gets activated. In this
study, we present a developed activity-based probe that is
capable of labeling all of the executioner caspases, including
caspase-6, both in intact cells and also in vivo. Using this probe,
we show that caspase-6 is activated independently of the other
downstream caspase-3 and -7. Furthermore, our results confirm
that caspase-6 activation proceeds through a series of partially
processed intermediates that have an ordered active site and
a unique structural conformation relative to the other executioner
caspases. This suggests that caspase-6 may exist in multiple
forms in the cell and that these forms may have relevance to
its diverse functional roles in the cell.ª2012 Elsevier Ltd All rights reserved 349
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label uncleaved, immature forms of caspase-6. These proforms
have not previously been shown to be active in living cells or
lysates. Recent studies using recombinant caspase-6 sug-
gested that cleavage of at least one site within the inter-
subunit linker, either Asp179 or Asp193, is required to activate
the enzyme (Klaiman et al., 2009). A noncleavable form of
caspase-6 (D179A/D193A) showed weak activity against a
fluorogenic VEID substrate in vitro; however, this activity was
not detected in lysates or cells (Klaiman et al., 2009).
Recent crystal structures of caspase-6 indicate that both the
zymogen and the unbound processed form adopt a conforma-
tion unique among all caspases in which the active-site residues
are misaligned (Baumgartner et al., 2009; Wang et al., 2010). It is
only upon substrate binding that a conformational change
occurs, allowing the formation of a canonical caspase active
site (Vaidya et al., 2011). Caspase-6 has also been suggested
to be capable of intramolecular autoactivation, a phenomenon
not observed by other executioner caspases (Wang et al.,
2010). This autoactivation occurs through intramolecular cleav-
age at Asp193, a site that is located near the catalytic Cys163
of the active site. If the shift in conformation is able to initiate
intramolecular cleavage, it is feasible that this shift could also
promote substrate processing, even without D193 cleavage. A
half-cleaved intermediate would result if intramolecular cleavage
at D193 did not occur in both molecules of the dimer simulta-
neously. Most of the active procaspase-6 detected in apoptotic
cells appears to be in complex with a cleaved molecule, as
indicated by immunoprecipitation experiments, suggesting that
cleavage occurs through a stepwise process. Whether or not
these intermediates are active against physiological substrates
remains unclear, and further studies are warranted.
Although caspase-6 is able to autoactivate, it is clear from our
studies that the activity of caspase-6 increases sharply upon
introduction of a death stimulus. It is currently unclear how
caspase-6 is prevented from autoactivating in the cell under
normal conditions. In addition to a conformational shift and
subsequent autocleavage, other factors likely contribute to its
full activation in vivo. Previous studies suggest that caspase-3
and -7 are responsible for this activation (Inoue et al., 2009;
Slee et al., 1999, 2001). However, our data suggest that full
maturation of caspase-6 can occur independently of these
proteases. Full activation may require cleavage by an initiator
protease or the release of an inhibitor, although endogenous
inhibitors of caspase-6 have yet to be described.
SIGNIFICANCE
In this study, we have improved upon the previous genera-
tion of fluorescent activity-based probes to detect caspase
activity in lysates, intact cells, tissues, andwhole organisms.
Compared to our previous probe AB50, LE22 shows in-
creased potency toward caspases with reduced off-target
labeling. Furthermore, LE22 is a fluorescent activity-based
probe capable of simultaneously monitoring the dynamics
of all executioner caspase activity during apoptosis in living
cells and tissues. Given these properties, LE22 is potentially
valuable for both preclinical and clinical applications where
detection of apoptosis may be beneficial (e.g., assessing350 Chemistry & Biology 19, 340–352, March 23, 2012 ª2012 Elsevieefficacy of chemotherapy response during cancer treatment
and identifying off-target effects, etc.). Caspase-6 has also
been demonstrated to have nonapoptotic roles in a number
of neurological disorders such as Huntington, Parkinson’s,
and Alzheimer’s diseases. Therefore, LE22 could also be
an important tool to assist in further dissection of the contri-
bution of caspase-6 activity during progression of these
diseases.
In addition to its potential clinical value, LE22 is also an
effective tool to aid in understanding basic mechanisms of
executioner caspase activation during apoptosis. In this
study, we used LE22 to demonstrate that caspase-6 is
activated in a manner distinct from caspase-3. Unlike
caspase-3, caspase-6 undergoes a conformational change
upon activation and substrate binding and can cleave sub-
strates in its full-length form. Additionally, we showed that
caspase-6 can reach full maturation and activation in the
absenceofcaspase-3orcaspase-7activity, suggestinghighly
regulated autoactivation or cleavage by other proteases.
Future studies will utilize LE22 to better define the activation
mechanisms and function of caspase-6 during apoptosis.
EXPERIMENTAL PROCEDURES
Compound Synthesis
All caspase probes and inhibitors were synthesized using solid-phase peptide
synthesis methods previously reported for P1-Asp-AOMKcompounds (Berger
et al., 2006; Edgington et al., 2009). The Cy5 fluorophore was synthesized
in house according to Mujumdar et al. (1993) and coupled to probes using
established methods (Berger et al., 2006; Edgington et al., 2009). Purity and
identity of all compounds were assessed by LC-MS using an Agilent HPLC
in tandem with an API 150 mass spectrometer (Applied Biosystems/SCIEX)
equipped with an electrospray interface.
Labeling of Intact Cells
Humancolorectal cancerCOLO205cells (ATCC)were seeded in six-well plates
(1.5 3 106/well) 24 hr prior to stimulation. Media were refreshed and anti-DR5
(20 mg/ml) was added for the indicated time. For intact cell labeling, probe
was added during the last 30min from1,0003 concentratedDMSOstock solu-
tions, yielding a final DMSO concentration of 0.1%. AB13 inhibitor, where indi-
cated, was added 30 min prior to probe addition. At t = 0, cells were scraped,
washed once with PBS, and resuspended in hypotonic lysis buffer containing
50 mM PIPES (pH 7.4), 10 mM KCl, 5 mM KCl2, 2 mM EDTA, 4 mM DTT, and
1% NP-40. Samples were snap-frozen in liquid N2 and centrifuged at 4
C,
and supernatants were solubilized with 43 sample buffer. Fifty micrograms
of total proteinwas resolved by 15%SDS-PAGEand scanned using a Typhoon
flatbed laser scanner (633 nm excitation/670 nm emission). RAW cells were
labeled by a similar procedure, except anti-DR5 was not added. 293T cell
extracts were prepared in a similar fashion, and caspase activation in these
extracts was initiated by the addition of purified cytochrome c from horse heart
(Sigma-Aldrich) at a concentration of 5 mMand dATP at 60 mM (Sigma-Aldrich).
Lysate Labeling
For labeling of lysates, experiments were carried out as above, except inhibitor
and probe were added after hypotonic lysis from 1003DMSO stock solutions,
where the final DMSO concentration was 1%. Inhibitor was added just prior to
addition of probe, and 43 sample buffer was added after 30 min of labeling.
Ten micrograms of total protein was analyzed by SDS-PAGE as above.
Immunoprecipitations
Samples from intact labeling experiments were immunoprecipitated from the
same samples, which had been boiled in SDS sample buffer. Samples from
lysate labeling were not boiled unless indicated. Total protein (50–100 mg)
was diluted in 500 ml RIPA buffer (PBS, 1 mM EDTA, 0.5% NP-40 [pH 7.4]).r Ltd All rights reserved
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10 min on ice before addition of a 40 ml slurry of prewashed protein A/G
agarose beads (Santa Cruz Biotechnology). Samples were shaken overnight
at 4C followed by washing four times with RIPA buffer and once with 0.9%
NaCl. Sample buffer (23) was added and beads were boiled followed by
SDS-PAGE analysis. All antibodies were purchased from Cell Signaling Tech-
nologies: cleaved caspase-6 (9761), caspase-6 (9162), cleaved caspase-3
(9661), cleaved caspase-7 (9491), caspase-8 (9746), and caspase-9 (9502).
Dexamethasone-Induced Thymocyte Apoptosis
All animal experiments were performed according to specific guidelines
approved by the Stanford Administrative Panel on Laboratory Animal Care.
Six-week-old female BALB/c mice were obtained from The Jackson
Laboratory. Each treatment group contained five mice. Mice were injected
intraperitoneally with water-soluble dexamethasone (Sigma; 50 mg/kg
dissolved in 100 ml sterile PBS) or PBS vehicle. Twelve hours later, mice
were injected intravenously by tail vein with 40 nmol probe in 10% DMSO/
PBS (1 mg/kg). For inhibitor-treated mice, AB46 (125 nmol in 20% DMSO/
PBS,3.3mg/kg) was administered by tail vein 20min prior to probe injection.
Four hours later, mice were anesthetized with isofluorane and killed by cervical
dislocation. Thymi were removed from all mice and kidney and liver from
vehicle control mice for assessment of off-target labeling. Organs were
imaged immediately using a PerkinElmer fluorescence-mediated tomography
(FMT) machine with a Cy5.5 filter and then homogenized in muscle lysis buffer
(1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, PBS [pH 7.4]). Total
protein (50 mg) was analyzed by SDS-PAGE as described above.
Anti-DR5 Antibody-Induced Tumor Apoptosis
Six-week-old female nude mice were obtained from Charles River. COLO205
xenografted tumors were established on their backs as described previously
(Edgington et al., 2009). Anti-DR5 antibody (10 mg/kg; Genentech) or vehicle
(10 mM histidine, 0.8% sucrose, 0.02% Tween-20 [pH 6]) was administered
via tail vein in a 100 ml volume. Twelve hours later, 40 nmol probe was
administered as above. After 1 hr, mice were imaged noninvasively using an
IVIS 100 system (Caliper Life Sciences). Mice were then killed as above.
Tumors were removed, imaged ex vivo using an FMT, and processed as
above. For tumor lysate labeling, tumors were harvested without administering
probe and labeled according to the protocol above. Four mice were used for
each treatment group and representative images are shown.
Recombinant Caspase-6 and Enzyme Kinetics
Full-length human caspase-6 was cloned in a pET23b expression vector with
a C-terminal 63His tag for expression in E. coli and purified as described
(Stennicke et al., 1999). Mutants were generated by a QuikChange Site-
Directed Mutagenesis Kit. Active-site concentration in the purified protein
preparations were determined by titration with the irreversible caspase inhib-
itor Z-VAD-FMK, and Vmax and KM values were determined with the substrate
Ac-VEID-AFC as described (Stennicke et al., 1999). Recombinant caspases
were labeled at a total protein concentration of 4 mM, as determined by A280,
with 10 mMLE22 for up to 3 hr at 37C.Gels were scanned on a Li-Cor Odyssey
infrared scanner at 700 nm to detect the Cy5 signal of the probe, stained with
GelCode Blue reagent (Thermo Scientific), and rescanned. The two images
were colored and overlaid in Adobe Photoshop 7.0.
Pore Limit PAGE and Western Blot
For pore limit PAGE of native proteins, 4%–20% polyacrylamide gels were
prepared and run at constant voltage (80 V) for 16 hr with cooling and buffer
recirculation between the reservoirs in 89 mM Tris, 2 mM EDTA, 89 mM boric
acid (pH 9) (Barrett et al., 1979). Size standards were catalase (232 kDa),
transferrin (81 kDa), BSA (67 kDa), and CrmA Thr345Arg mutant (Tewari
et al., 1995) (39 kDa).
For western blotting, the proteins were transferred to nitrocellulose
membrane and probed for total and cleaved caspase-3 (Cell Signaling
Technology; 9662 and 9661, respectively) or full-length and cleaved
caspase-6 (Upstate Biotechnology, 06-691 and Millipore, AB10512, respec-
tively). Secondary antibody was donkey anti-rabbit IRDye 800CW from Li-Cor.
Blots were scanned on an Odyssey infrared scanner (Li-Cor).Chemistry & Biology 19, 3SUPPLEMENTAL INFORMATION
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